The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the initial UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e. NeuroMabs): for immunocytochemical-based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.

The UC Davis/NIH NeuroMab Facility was initially funded in 2005 with a five-year U24 cooperative grant from NINDS and NIMH. The initial goal of the facility for this funding period is to generate a library of novel NeuroMabs against neuronal proteins, initially focusing on membrane proteins (receptors/channels/transporters), synaptic proteins, other neuronal signaling molecules, and proteins with established links to disease states. The scope of the facility was expanded with supplements from the NIH Blueprint for Neuroscience Research to include neurodevelopmental targets, the NIH Roadmap for Medical Research to include epigenetics targets, and NIH Office of Rare Diseases Research to include rare disease targets. Funding was renewed for an additional five years in 2010. These NeuroMabs will then be produced on a large scale and made available to the neuroscience research community on an inexpensive basis as tissue culture supernatants or purified immunoglobulin by our distribution contractor Antibodies Incorporated. To see the catalog of available antibodies go here.

The UC Davis/NIH NeuroMab Facility is also accepting suggestions as to potential targets. Requestors should supply the UC Davis/NIH NeuroMab Facility with a scientific justification as to the biological importance of the target molecule, the importance of these reagents to the national neuroscience community, and the availability and suitability of existing polyclonal and/or monoclonal antibodies. Also include a list of reagents (synthetic peptides, fusions proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) that will be made available to the UC Davis/NIH NeuroMab Facility staff to facilitate the development and characterization of these NeuroMabs. Submit this information to NeuroMab here. The UC Davis/NIH NeuroMab Facility advisory board, acting in concert with NIH program officials, will then prioritize the request in the UC Davis/NIH NeuroMab Facility queue. Note that all hybridomas and mAbs developed by the UC Davis/NIH NeuroMab Facility are the property of the Regents of the University of California.

The UC Davis/NIH NeuroMab Facility serves as a resource to the entire neuroscience community by providing high quality reagents that will serve as critical links between information emerging from genomic efforts and future proteomic approaches to brain function. Moreover, the unique neuroscience-based approach that the UC Davis/NIH NeuroMab Facility uses will yield reliable antibodies that might not otherwise be available, and the comprehensive biochemical and immunohistochemical verification will save countless investigators the time, money and effort of attempting to use expensive yet suboptimal reagents in their research.

UC Davis makes no warranties, either expressed or implied, concerning the accuracy, completeness, reliability, or suitability of the information contained on these Web pages or of the security or privacy of any information collected by these Web pages. All views expressed in the Web site are those of the author and not UC Davis.